Viracta Therapeutics, Inc.
(NASDAQ : SNSS)

( )
SNSS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -5.06%150.000.0%$678.53m
AMGNAmgen, Inc. -0.35%249.701.5%$585.90m
GILDGilead Sciences, Inc. -1.27%65.181.0%$429.55m
VRTXVertex Pharmaceuticals, Inc. -1.65%294.291.9%$402.50m
REGNRegeneron Pharmaceuticals, Inc. -1.81%624.832.6%$354.90m
ILMNIllumina, Inc. -1.86%209.063.3%$307.20m
SNSSSunesis Pharmaceuticals, Inc. 2.22%4.150.7%$290.10m
NVAXNovavax, Inc. -5.56%37.1875.7%$231.38m
BIIBBiogen, Inc. -0.57%216.341.8%$185.52m
BNTXBioNTech SE -2.91%147.610.0%$150.86m
SAVACassava Sciences, Inc. 2.92%26.470.0%$120.22m
GOVXGeoVax Labs, Inc. -12.83%1.970.0%$104.86m
BMRNBioMarin Pharmaceutical, Inc. -1.98%92.964.2%$97.95m
CRSPCRISPR Therapeutics AG 0.57%72.150.6%$91.12m
EXASEXACT Sciences Corp. -2.73%38.4817.6%$84.05m

Company Profile

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.